Web-based symptom support after radioactive iodine for differentiated thyroid cancer
A Pilot Randomized Controlled Trial of the Use of a Website About Radioactive Iodine Symptom Management in Patients With Thyroid Cancer
NA · Georgetown University · NCT06853925
This will test a four-week web program called RAI Support to help adults treated with radioactive iodine for differentiated thyroid cancer manage symptoms and improve overall quality of life compared with usual online information.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 88 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Georgetown University (other) |
| Locations | 1 site (Washington D.C., District of Columbia) |
| Trial ID | NCT06853925 on ClinicalTrials.gov |
What this trial studies
Adults with differentiated (papillary or follicular) thyroid cancer who received radioactive iodine within the past three years and have mild-to-moderate symptoms are assigned to either RAI Support or a publicly available informational website for four weeks. RAI Support provides educational resources and symptom-management strategies through an online platform accessible by computer, tablet, or smartphone. The study measures usability and health-related quality of life to see if the web program improves overall well-being compared with treatment as usual. This pilot work focuses on feasibility and preliminary benefit among English-speaking participants with internet access.
Who should consider this trial
Good fit: Adults (18+) with papillary or follicular thyroid cancer who had radioactive iodine within the past three years, report mild-to-moderate RAI-related symptoms, can consent in English, and have internet access are ideal candidates.
Not a fit: People with severe cognitive or psychiatric impairment, major hearing problems, no internet access, non-English speakers, or those whose RAI was more than three years ago may not receive benefit from this online program.
Why it matters
Potential benefit: If successful, the program could give thyroid cancer survivors an easy-to-use online toolkit to reduce symptoms and improve daily well-being after radioactive iodine.
How similar studies have performed: Internet-based symptom-management programs for cancer patients have shown mixed but promising results, while RAI-specific digital interventions remain relatively untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 or older (papillary or follicular carcinoma) * Diagnosed with differentiated thyroid cancer * Received radioactive iodine (RAI) treatment less than or equal to three years ago. * Mild to moderate symptoms of RAI * Able to provide informed consent in English * Access to a computer, tablet, or smartphone with internet connectivity Exclusion Criteria: * A condition that precludes providing informed consent or completing study procedures (cognitive or psychiatric condition, hearing problems) as identified by the patient's physician or as assessed by a trained study team member.
Where this trial is running
Washington D.C., District of Columbia
- Georgetown University — Washington D.C., District of Columbia, United States (RECRUITING)
Study contacts
- Principal investigator: Alaina Carr, PhD — Georgetown University
- Study coordinator: Alaina L Carr, PhD
- Email: cancercarestudy@georgetown.edu
- Phone: 202-687-0958
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Thyroid Neoplasms, symptom burden, self efficacy, feasibility studies, internet-based intervention, pilot projects, neoplasms, radioactive iodine treatment